• Politics
  • Diversity, equity and inclusion
  • Financial Decision Making
  • Telehealth
  • Patient Experience
  • Leadership
  • Point of Care Tools
  • Product Solutions
  • Management
  • Technology
  • Healthcare Transformation
  • Data + Technology
  • Safer Hospitals
  • Business
  • Providers in Practice
  • Mergers and Acquisitions
  • AI & Data Analytics
  • Cybersecurity
  • Interoperability & EHRs
  • Medical Devices
  • Pop Health Tech
  • Precision Medicine
  • Virtual Care
  • Health equity

MAP Bags $25M in Funding to Reduce Addiction Relapse


The company provides telehealth services to patients with substance use disorder to improve outcomes.

video counseling

MAP Health Management, a provider of peer recovery support services and data insights for people with substance use disorder, announced today that it has completed a $25 million Series A funding round, led by Aetna.

The Levenson Family and other private investors also participated in the funding round.

Funding will be used to expand the company’s geographical base of operations and its patient enrollment strategy beyond addiction treatment providers to also include emergency care locations, primary care providers and pharmacies.

Founded in 2011, MAP Health Management aims to improve outcomes for the millions of people diagnosed and treated for addiction by implementing longer-term support. Support is provided through telehealth platforms accessible via phone or video sessions and are conducted by peer recovery specialists. The specialists leverage lived experience in recovery and extensive training to support individuals and their families through the transition from treatment to long-term recovery.

“In providing peer support to our members and their families in their behavioral health recovery journey, MAP’s services support one of the core components in our work to transform behavioral health service delivery,” said Antonio J. Rocchino, senior director of network management at Aetna.

Recently, there has been a rise of telehealth and digital health services for patients with substance use disorder.

Last year, the U.S. Food and Drug Administration approved reSET and reSET-O, digital therapeutic applications created by Sandoz and Pear Therapeutics for opioid addiction and substance use disorder.

Get the best insights in healthcare analytics directly to your inbox.

Related Coverage:

FDA OKs Marketing of Mobile App for Substance Abuse Disorder

Telehealth Can Provide a Solution for Millennials with Depression

Reducing Depression Symptoms with Digital Health Tools

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.